VJHemOnc is committed to improving our service to you

SOHO 2020 | Updates from the ECHELON-1 study

VJHemOnc is committed to improving our service to you

David J. Straus

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, updates us on long term results of the ECHELON-1 study (NCT01712490), evaluating brentuximab vedotin, an antibody-drug conjugate, with chemotherapy for stage III/IV classical Hodgkin lymphoma. Furthermore, Dr Straus elaborates on an ongoing study evaluating BV + ABD against nivolumab + ABD. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter